nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—Gastrointestinal symptom NOS—Hydroxyurea—head and neck cancer	0.0331	0.0331	CcSEcCtD
Ceftazidime—Application site pain—Fluorouracil—head and neck cancer	0.0318	0.0318	CcSEcCtD
Ceftazidime—Reaction gastrointestinal—Docetaxel—head and neck cancer	0.0303	0.0303	CcSEcCtD
Ceftazidime—Local reaction—Fluorouracil—head and neck cancer	0.0253	0.0253	CcSEcCtD
Ceftazidime—Gastrointestinal symptom NOS—Fluorouracil—head and neck cancer	0.0238	0.0238	CcSEcCtD
Ceftazidime—Encephalopathy—Fluorouracil—head and neck cancer	0.0218	0.0218	CcSEcCtD
Ceftazidime—Skin exfoliation—Hydroxyurea—head and neck cancer	0.0186	0.0186	CcSEcCtD
Ceftazidime—Phlebitis—Vinblastine—head and neck cancer	0.018	0.018	CcSEcCtD
Ceftazidime—Oral candidiasis—Docetaxel—head and neck cancer	0.0159	0.0159	CcSEcCtD
Ceftazidime—Inflammation—Fluorouracil—head and neck cancer	0.0144	0.0144	CcSEcCtD
Ceftazidime—Dermatitis atopic—Docetaxel—head and neck cancer	0.0137	0.0137	CcSEcCtD
Ceftazidime—Coma—Fluorouracil—head and neck cancer	0.0128	0.0128	CcSEcCtD
Ceftazidime—Pancytopenia—Vinblastine—head and neck cancer	0.0127	0.0127	CcSEcCtD
Ceftazidime—Thrombophlebitis—Fluorouracil—head and neck cancer	0.0117	0.0117	CcSEcCtD
Ceftazidime—Pancytopenia—Hydroxyurea—head and neck cancer	0.0116	0.0116	CcSEcCtD
Ceftazidime—Neutropenia—Hydroxyurea—head and neck cancer	0.0114	0.0114	CcSEcCtD
Ceftazidime—Agranulocytosis—Vinblastine—head and neck cancer	0.0111	0.0111	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.0111	0.0111	CcSEcCtD
Ceftazidime—Infestation NOS—Hydroxyurea—head and neck cancer	0.0109	0.0109	CcSEcCtD
Ceftazidime—Infestation—Hydroxyurea—head and neck cancer	0.0109	0.0109	CcSEcCtD
Ceftazidime—Haemoglobin—Vinblastine—head and neck cancer	0.0108	0.0108	CcSEcCtD
Ceftazidime—Haemorrhage—Vinblastine—head and neck cancer	0.0107	0.0107	CcSEcCtD
Ceftazidime—Inflammation—Docetaxel—head and neck cancer	0.0104	0.0104	CcSEcCtD
Ceftazidime—Lethargy—Fluorouracil—head and neck cancer	0.0104	0.0104	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.0103	0.0103	CcSEcCtD
Ceftazidime—Haemoglobin—Hydroxyurea—head and neck cancer	0.00982	0.00982	CcSEcCtD
Ceftazidime—Haemorrhage—Hydroxyurea—head and neck cancer	0.00977	0.00977	CcSEcCtD
Ceftazidime—Hallucination—Hydroxyurea—head and neck cancer	0.00972	0.00972	CcSEcCtD
Ceftazidime—Colitis—Docetaxel—head and neck cancer	0.00971	0.00971	CcSEcCtD
Ceftazidime—Skin exfoliation—Docetaxel—head and neck cancer	0.00965	0.00965	CcSEcCtD
Ceftazidime—Candida infection—Docetaxel—head and neck cancer	0.00965	0.00965	CcSEcCtD
Ceftazidime—Angiopathy—Hydroxyurea—head and neck cancer	0.00887	0.00887	CcSEcCtD
Ceftazidime—Eosinophilia—Fluorouracil—head and neck cancer	0.0087	0.0087	CcSEcCtD
Ceftazidime—Phlebitis—Docetaxel—head and neck cancer	0.00852	0.00852	CcSEcCtD
Ceftazidime—Thrombophlebitis—Docetaxel—head and neck cancer	0.00848	0.00848	CcSEcCtD
Ceftazidime—Leukopenia—Vinblastine—head and neck cancer	0.00835	0.00835	CcSEcCtD
Ceftazidime—Pancytopenia—Fluorouracil—head and neck cancer	0.00835	0.00835	CcSEcCtD
Ceftazidime—Convulsion—Vinblastine—head and neck cancer	0.00808	0.00808	CcSEcCtD
Ceftazidime—Hot flush—Docetaxel—head and neck cancer	0.00785	0.00785	CcSEcCtD
Ceftazidime—Infestation NOS—Fluorouracil—head and neck cancer	0.00784	0.00784	CcSEcCtD
Ceftazidime—Infestation—Fluorouracil—head and neck cancer	0.00784	0.00784	CcSEcCtD
Ceftazidime—Menopausal symptoms—Docetaxel—head and neck cancer	0.00778	0.00778	CcSEcCtD
Ceftazidime—Renal impairment—Docetaxel—head and neck cancer	0.00771	0.00771	CcSEcCtD
Ceftazidime—Leukopenia—Hydroxyurea—head and neck cancer	0.00762	0.00762	CcSEcCtD
Ceftazidime—Lethargy—Docetaxel—head and neck cancer	0.00749	0.00749	CcSEcCtD
Ceftazidime—Thrombocytopenia—Vinblastine—head and neck cancer	0.00745	0.00745	CcSEcCtD
Ceftazidime—Convulsion—Hydroxyurea—head and neck cancer	0.00737	0.00737	CcSEcCtD
Ceftazidime—Agranulocytosis—Fluorouracil—head and neck cancer	0.00731	0.00731	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00719	0.00719	CcSEcCtD
Ceftazidime—Haemoglobin—Fluorouracil—head and neck cancer	0.00707	0.00707	CcSEcCtD
Ceftazidime—Haemorrhage—Fluorouracil—head and neck cancer	0.00703	0.00703	CcSEcCtD
Ceftazidime—Paraesthesia—Vinblastine—head and neck cancer	0.00684	0.00684	CcSEcCtD
Ceftazidime—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00681	0.00681	CcSEcCtD
Ceftazidime—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.0068	0.0068	CcSEcCtD
Ceftazidime—Skin disorder—Hydroxyurea—head and neck cancer	0.00674	0.00674	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.00661	0.00661	CcSEcCtD
Ceftazidime—Pain—Vinblastine—head and neck cancer	0.00651	0.00651	CcSEcCtD
Ceftazidime—Bronchospasm—Docetaxel—head and neck cancer	0.00624	0.00624	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00623	0.00623	CcSEcCtD
Ceftazidime—Pancytopenia—Docetaxel—head and neck cancer	0.00602	0.00602	CcSEcCtD
Ceftazidime—Abdominal pain—Vinblastine—head and neck cancer	0.00602	0.00602	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00599	0.00599	CcSEcCtD
Ceftazidime—Pain—Hydroxyurea—head and neck cancer	0.00594	0.00594	CcSEcCtD
Ceftazidime—Neutropenia—Docetaxel—head and neck cancer	0.00593	0.00593	CcSEcCtD
Ceftazidime—Vision blurred—Fluorouracil—head and neck cancer	0.00577	0.00577	CcSEcCtD
Ceftazidime—Infestation—Docetaxel—head and neck cancer	0.00566	0.00566	CcSEcCtD
Ceftazidime—Infestation NOS—Docetaxel—head and neck cancer	0.00566	0.00566	CcSEcCtD
Ceftazidime—Hypersensitivity—Vinblastine—head and neck cancer	0.00561	0.00561	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00561	0.00561	CcSEcCtD
Ceftazidime—Renal failure—Docetaxel—head and neck cancer	0.00556	0.00556	CcSEcCtD
Ceftazidime—Jaundice—Docetaxel—head and neck cancer	0.00551	0.00551	CcSEcCtD
Ceftazidime—Body temperature increased—Hydroxyurea—head and neck cancer	0.00549	0.00549	CcSEcCtD
Ceftazidime—Leukopenia—Fluorouracil—head and neck cancer	0.00548	0.00548	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00535	0.00535	CcSEcCtD
Ceftazidime—Convulsion—Fluorouracil—head and neck cancer	0.00531	0.00531	CcSEcCtD
Ceftazidime—Agranulocytosis—Docetaxel—head and neck cancer	0.00528	0.00528	CcSEcCtD
Ceftazidime—Diarrhoea—Vinblastine—head and neck cancer	0.00521	0.00521	CcSEcCtD
Ceftazidime—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00512	0.00512	CcSEcCtD
Ceftazidime—Haemoglobin—Docetaxel—head and neck cancer	0.0051	0.0051	CcSEcCtD
Ceftazidime—Haemorrhage—Docetaxel—head and neck cancer	0.00508	0.00508	CcSEcCtD
Ceftazidime—Dizziness—Vinblastine—head and neck cancer	0.00503	0.00503	CcSEcCtD
Ceftazidime—Anaphylactic shock—Fluorouracil—head and neck cancer	0.005	0.005	CcSEcCtD
Ceftazidime—Nervous system disorder—Fluorouracil—head and neck cancer	0.0049	0.0049	CcSEcCtD
Ceftazidime—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00489	0.00489	CcSEcCtD
Ceftazidime—Vomiting—Vinblastine—head and neck cancer	0.00484	0.00484	CcSEcCtD
Ceftazidime—Erythema multiforme—Docetaxel—head and neck cancer	0.0048	0.0048	CcSEcCtD
Ceftazidime—Headache—Vinblastine—head and neck cancer	0.00477	0.00477	CcSEcCtD
Ceftazidime—Diarrhoea—Hydroxyurea—head and neck cancer	0.00475	0.00475	CcSEcCtD
Ceftazidime—Flushing—Docetaxel—head and neck cancer	0.00471	0.00471	CcSEcCtD
Ceftazidime—Hypotension—Fluorouracil—head and neck cancer	0.00467	0.00467	CcSEcCtD
Ceftazidime—Angiopathy—Docetaxel—head and neck cancer	0.00461	0.00461	CcSEcCtD
Ceftazidime—Dizziness—Hydroxyurea—head and neck cancer	0.00459	0.00459	CcSEcCtD
Ceftazidime—Immune system disorder—Docetaxel—head and neck cancer	0.00459	0.00459	CcSEcCtD
Ceftazidime—Nausea—Vinblastine—head and neck cancer	0.00452	0.00452	CcSEcCtD
Ceftazidime—Paraesthesia—Fluorouracil—head and neck cancer	0.00449	0.00449	CcSEcCtD
Ceftazidime—Vomiting—Hydroxyurea—head and neck cancer	0.00441	0.00441	CcSEcCtD
Ceftazidime—Rash—Hydroxyurea—head and neck cancer	0.00438	0.00438	CcSEcCtD
Ceftazidime—Dermatitis—Hydroxyurea—head and neck cancer	0.00437	0.00437	CcSEcCtD
Ceftazidime—Headache—Hydroxyurea—head and neck cancer	0.00435	0.00435	CcSEcCtD
Ceftazidime—Dysgeusia—Docetaxel—head and neck cancer	0.00433	0.00433	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00431	0.00431	CcSEcCtD
Ceftazidime—Pain—Fluorouracil—head and neck cancer	0.00427	0.00427	CcSEcCtD
Ceftazidime—Nausea—Hydroxyurea—head and neck cancer	0.00412	0.00412	CcSEcCtD
Ceftazidime—Urticaria—Fluorouracil—head and neck cancer	0.00397	0.00397	CcSEcCtD
Ceftazidime—Leukopenia—Docetaxel—head and neck cancer	0.00396	0.00396	CcSEcCtD
Ceftazidime—Body temperature increased—Fluorouracil—head and neck cancer	0.00395	0.00395	CcSEcCtD
Ceftazidime—Convulsion—Docetaxel—head and neck cancer	0.00383	0.00383	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00374	0.00374	CcSEcCtD
Ceftazidime—Hypersensitivity—Fluorouracil—head and neck cancer	0.00368	0.00368	CcSEcCtD
Ceftazidime—Anaphylactic shock—Docetaxel—head and neck cancer	0.00361	0.00361	CcSEcCtD
Ceftazidime—Nervous system disorder—Docetaxel—head and neck cancer	0.00354	0.00354	CcSEcCtD
Ceftazidime—Pruritus—Fluorouracil—head and neck cancer	0.00354	0.00354	CcSEcCtD
Ceftazidime—Thrombocytopenia—Docetaxel—head and neck cancer	0.00353	0.00353	CcSEcCtD
Ceftazidime—Skin disorder—Docetaxel—head and neck cancer	0.0035	0.0035	CcSEcCtD
Ceftazidime—Diarrhoea—Fluorouracil—head and neck cancer	0.00342	0.00342	CcSEcCtD
Ceftazidime—Hypotension—Docetaxel—head and neck cancer	0.00337	0.00337	CcSEcCtD
Ceftazidime—Dizziness—Fluorouracil—head and neck cancer	0.0033	0.0033	CcSEcCtD
Ceftazidime—Paraesthesia—Docetaxel—head and neck cancer	0.00324	0.00324	CcSEcCtD
Ceftazidime—Vomiting—Fluorouracil—head and neck cancer	0.00318	0.00318	CcSEcCtD
Ceftazidime—Rash—Fluorouracil—head and neck cancer	0.00315	0.00315	CcSEcCtD
Ceftazidime—Dermatitis—Fluorouracil—head and neck cancer	0.00315	0.00315	CcSEcCtD
Ceftazidime—Headache—Fluorouracil—head and neck cancer	0.00313	0.00313	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00311	0.00311	CcSEcCtD
Ceftazidime—Pain—Docetaxel—head and neck cancer	0.00308	0.00308	CcSEcCtD
Ceftazidime—Nausea—Fluorouracil—head and neck cancer	0.00297	0.00297	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00295	0.00295	CcSEcCtD
Ceftazidime—Abdominal pain—Docetaxel—head and neck cancer	0.00285	0.00285	CcSEcCtD
Ceftazidime—Body temperature increased—Docetaxel—head and neck cancer	0.00285	0.00285	CcSEcCtD
Ceftazidime—Hypersensitivity—Docetaxel—head and neck cancer	0.00266	0.00266	CcSEcCtD
Ceftazidime—Pruritus—Docetaxel—head and neck cancer	0.00255	0.00255	CcSEcCtD
Ceftazidime—Diarrhoea—Docetaxel—head and neck cancer	0.00247	0.00247	CcSEcCtD
Ceftazidime—Dizziness—Docetaxel—head and neck cancer	0.00239	0.00239	CcSEcCtD
Ceftazidime—Vomiting—Docetaxel—head and neck cancer	0.00229	0.00229	CcSEcCtD
Ceftazidime—Rash—Docetaxel—head and neck cancer	0.00227	0.00227	CcSEcCtD
Ceftazidime—Dermatitis—Docetaxel—head and neck cancer	0.00227	0.00227	CcSEcCtD
Ceftazidime—Headache—Docetaxel—head and neck cancer	0.00226	0.00226	CcSEcCtD
Ceftazidime—Nausea—Docetaxel—head and neck cancer	0.00214	0.00214	CcSEcCtD
